

Differential Gene Expression Profile in Essential Hypertension

Ping Yang

*Department of Internal Medicine and Cardiology, China-Japan Union Hospital,
Norman Bethune College of Medicine, Jilin University, Changchun,
China*

1. Introduction

Essential hypertension affects 20-30% of the population worldwide and contributes significantly to mortality and morbidity^[1] from cerebrovascular diseases, myocardial infarction, congestive heart failure and renal insufficiency. Essential hypertension is a prevalent disorder that leads to significant morbidity and mortality. Essential hypertension is defined as chronically elevated arterial pressure resulting from an unknown etiology. Intrinsically, it is a complex, heterogeneous, multifactorial syndrome to which environmental factors are partly responsible for. A lineup of aberrant environmental factors, including dietary salt intake^[2,3,4], body weight^[5,6], physical inactivity^[7,8], physical stress^[9,10], cigarette smoking ^[11-14], alcohol consumption^[15-18] and inadequate potassium consumption^[19,20] contribute to essential hypertension, possibly by infuriating genetically programmed susceptibilities. Results from twins, adoptive and population studies suggest high degree of similarity of blood pressure values, thus indicating the importance of genetic variables in essential hypertension etiology^[21-25]. It is assumed that blood pressure is under the control of a large number of genes each of which has only relatively mild effects.

Despite progress in genomic and statistical tools, identification of genes involved in complex cardiovascular traits such as hypertension remains a major challenge. Several strategies have been developed so far. Of these approaches developed, gene expression techniques hold vast promises as functional roles of gene products are determined among diverse biological processes^[26]. Gene expression profiling has become an overshadowing tool for discovery in medicine. Genes have additive function of working together; therefore expression levels of these groups of gene can be monitored through gene expression studies.

At present, differential gene expression between two sets of biological samples is carried out by utilizing techniques such as Northern blot analysis, serial analysis of gene expression (SAGE), differential display reverse transcription-PCR (DDRT-PCR) and Dot Blot analysis ^[26,27]. The drawback of these techniques is that large numbers of genes cannot be analyzed simultaneously. What's more, with Northern blot limited number of mRNAs may be examined simultaneously and quality and quantification of expression are negatively affected^[28]. Although the strengths of SAGE are remarkable, extensive DNA sequencing is technically difficult and formidable. With DDRT-PCR, simultaneous discovery of multiple differences in gene expression is possible; however, screening is not based on identity but in

mRNA length^[29]. Dot blot analysis is less time consuming, however, no information on the size of the target biomolecules is offered.

DNA microarray technology has the potential to overcome these limitations, as it has allowed unprecedented analysis of thousands of genes in a high-throughput form. On account of its high-throughput expression profiling, DNA microarray technology has become the predominant assay of choice in clinical medicine. This review, to a great extent looks at studies that used gene expression microarray technology in hypertension research to provide information on the disease specific risk profiles and pathology.

2. Methods

A literature search of the PUBMED database, using the medical headings “hypertension,” “blood pressure,” “gene expression,” and “microarray analysis,” will be conducted. The search will include published studies in human beings and as well as experimental models. Additionally, a search will be performed using references cited in original study articles and reviews and if copies of articles cannot be accessed, authors will be contacted.

2.1 Methods for the study of gene expression

Methods used to profile gene expression include Northern blot analysis, serial analysis of gene expression, differential display, dot blot analysis, subtractive hybridization and microarray hybridization.

2.2 Northern blot analysis

Although more sensitive gene expression techniques have emerged over the last decade, Northern blot analysis remains the standard for detection and quantitation of mRNA. Northern blotting has proven very effective in evaluating the expression levels of troponin c in chicken skeleton and cardiac muscles^[30], arterial natriuretic factor mRNA and peptide in the human heart during development^[31], myosin heavy chain and actin^[32]. It is remarkable in that it allows a direct relative comparison of message abundance between samples on a single blot. Regrettably, this technique requires large quantities of RNA and is prone to significant experimental manipulation for each of the genes examined. Taniguchi et al compared Northern blotting analyses with DNA microarrays and discovered Northern blotting to be more sensitive and consistent than DNA microarrays^[33]. Despite the fact large-scale transcriptome analysis experiments are not performable with Northern blotting, it is however, conveniently used in studies focused on analysis of small numbers of genes.

2.3 Serial analysis of gene expression (SAGE)

Serial analysis of gene expression method was recently discovered at John Hopkins University with the intention to create a global picture of cellular function. SAGE enables tagged short sequences of reverse transcribed cDNA to be prepared and identified by DNA sequencing^[34]. The SAGE technique can be used to obtain large-scale cardiac gene expression^[35,36]. Even supposing the quantitative and cumulative data this technique presents, one limitation is the identification of the genes reported by the SAGE.

2.4 Differential Display (DD)

Differential display was first introduced by Liang and Pardee in 1992^[37]. This technique involves the identification and analysis of differentially expressed genes at the mRNA level. The basic principle of differential display is to use short primers in combination with oligo-dT primers to amplify and visualize mRNA in a cell. DD has been a powerful and successful method due to its inherent simplicity to detect changes in mRNA profiles among multiple samples without any prior knowledge of genomic information of the organism studied.

2.5 Dot blot analysis

Dot blot is an immunological technique and is a simplification of northern blotting, southern blotting, or western blotting methods^[38,39]. This method identifies a known protein in a biological sample. Dot blot differs from western blotting in that protein samples are separated electrophoretically but are spotted through circular templates directly onto the membrane or paper substrate. The characteristic of dot blot is the use of immunodetection to identify a specific protein.

2.6 Subtractive hybridization

Subtractive hybridization is a powerful technique that was first described by Sargent and Dawid for creating cDNA libraries and generating probes of genes expressed differentially^[40]. This technique is based on the principle that nucleic acid sequences in common with the two populations can form hybrids. It is the first tool used for identifying differentially expressed genes on a global scale. With Subtractive hybridization, the isolation of genes does not require prior knowledge of their sequence or identity.

2.7 Microarray hybridization

Microarray analysis, is a high through-put technique that provides an important tool to study the global patterns of gene expression. Two of the most commonly used microarrays for gene-expression measurements are oligonucleotide GeneChip expression arrays by Affymetrix and cDNA microarrays. Oligonucleotide microarrays contain sets of multiple 25 mer oligonucleotide probes specific for each gene or expressed-sequence tag (EST), whereas cDNA microarrays generally contain longer oligonucleotide probes (usually 25 to 60 bases) or cDNA probes (usually 500 to 1,000 bases) that stand for the specific gene, so cDNA microarrays are more commonly used. It permits quantitative analysis of RNAs transcribed from both known and unknown genes. Microarray analysis is based on the principle of complementary, single-stranded, nucleic acid sequences forming double-stranded hybrids. This technology can simultaneously measure the expression levels of thousands of genes within a particular mRNA sample in a high-through put manner^[42,43].

2.8 Research objects

For the DNA microarrays, we could study human or animal models. The spontaneously hypertensive rats (SHR) are the most popular used animal models for essential hypertension, and the Lyon hypertensive rats^[44] follows behind, compared to normotensive Wistar Kyoto rats (WKY).

2.9 Samples

We mainly use peripheral blood samples^[45] in human and vascular smooth muscle cell (VSMC)^[46,47], adrenal^[44], heart^[2,48,49] and kidney^[2,44,53-56,58] in animal models.

2.10 Software tools

The large amount of information generated from microarrays has been a great strength, but is sometimes seen as a frustrating weakness because of the inability to process experimental data easily, assess the data quality, manage multiple data sets and mine the data with user-friendly tools. Most of the microarrays have the suite of software to deal with the results, such as the Affymetrix software for the Affymetrix microarrays. The related software is listed as follows. The software was not designed to do complex statistical analyses and visualization. Rather, it was designed to help the researcher narrow their search from tens of thousands of gene candidates to several hundred or fewer that meet specific, but adjustable criteria.

2.11 Altered gene expression in blood

Peripheral blood gene expression has the potential to provide information on underlying pathologic states. Several authors have used whole blood as a surrogate tissue for gene expression in patients with essential hypertension. In their study, Korkor et al identified 49 differentially expressed genes; 31 up regulated and 18 down regulated genes. Amongst genes found to be altered include CD36, SLC4A1, NET1, SESN3, ZNF652, PRDX6, HIP1, FOLR3, ERAP1, CFD^[45]. Most of the genes that were differentially expressed were related to immune/inflammatory responses. In a study conducted by Chon et al, gene expression patterns of hypertensives revealed 680 genes that were upregulated as compared to patients who were normotensive on medication^[52]. Timofeeva AV et al reported that 22 genes were up-regulated and 18 genes down-regulation in atherosclerotic aorta compared with normal vessel through cDNA microarray, among these, CD53, SPI1, FPRL2, SPP1, CTSD, ACP5, LCP1, CTSA and LIPA genes are up-regulated both in peripheral blood leukocytes from EH patients and in atherosclerotic lesions of human aorta. The majority of these genes significantly positively correlated with hypertension stage as well as with histological grading of atherosclerotic lesions^[53].

2.12 Altered gene expression in the tissues and organs

Koo et al reported altered gene expression in the kidneys of adults of spontaneously hypertension rats^[54]. Analyzing mRNA from 8-week-old female SHR and age-matched female WKY, 43 up-regulated and 31 down-regulated genes were revealed. The upregulation of stearyl-CoA desaturase-2 gene and downregulation of taurine/betalanine transporter gene in SHR compared with WKY rat were reported and in the SHR group, dysregulations of several genes involved in lipid metabolism was also revealed. Seubert et al investigated renal gene expression profiles in SHR and WKY animals at prehypertensive (3 wk of age) and hypertensive (9 wk of age) stages and identified 22 genes at 3 wk of age and 104 genes at 9 wk of age that were differentially expressed in SHR compared with WKY^[55]. There are some other studies identified differential gene expression in animal models of essential hypertension that are listed in table 2.

Results	References
49 genes were found differentially expressed in essential hypertension, 31 up regulated and 18 down regulated.	Korkor et al. (45)
680 genes were found differentially expressed in untreated hypertensives compared to normotensive controls. On the other hand, only 7 genes were differentially expressed in treated hypertensives compared to normotensive controls.	Chen et al. (52)
22 genes were up-regulated and 18 genes demonstrated down-regulation in atherosclerotic aorta compared with normal vessel, CD53, SPI1, FPRL2, SPP1, CTSD, ACP5, LCPI, CTSA and LIPA genes are up-regulated in peripheral blood leukocytes from EH patients and in atherosclerotic lesions of human aorta. The majority of these genes significantly ($p < 0.005$) positively ($r > 0.5$) correlated with AH stage as well as with histological grading of atherosclerotic lesions.	Timofeeva AV et al (53)

Table 1. Differential gene expression profiling in human blood in essential hypertension.

Animal model and the control group	Tissue	Microarray platform	Software	Observations	References
SDR, SHR and WKY	Area postrema	Rat Genechip 230 2.0 microarrays	GeneSpring GX11	'hypertension-related' elements revealed genes that are involved in the regulation of both blood pressure and immune function	Hindmarch CC et al. (46)
eET-1 and wild-type (WT) mice	mesenteric arteries	Illumina microarray, validation by qPCR of 4 genes	Flexarray software for the microarray results, and Ingenuity Pathway Analysis for the gene lists.	increased endothelial ET-1 expression results in early changes in gene expression in the vascular wall that enhance lipid biosynthesis and accelerate progression of atherosclerosis.	Simeone SM et al. (47)
SHR and BNR for the control	Kidney	Affymetrix U34A-C microarrays, validation by RT-PCR, DNA sequencing and RFLP analyses.	Solexa Tag analysis	88 transcripts are identified to be differentially expressed between SHRs and BN rats.	Johnson MD et al. (2)

Animal model and the control group	Tissue	Microarray platform	Software	Observations	References
normal (normotensive) Wistar rats, DOCA-salt hypertensive (DH) rats, DH rats treated with AG1478, and DH rats treated with FPTIII	kidney	Codelink Uniset Rat 1Bioarrays	Affymetrix Scanner 428, Imagen and Genowiz softwares by Ocimum Biosolutions (India) and subjected to arsinh transformation	2398 genes were upregulated and only 50 genes were downregulated by more than 2-fold in hypertensive rat kidneys compared to non-diseased controls.	Benter IF et al. (44)
SHR	aorta	GeneChip® Affymetrix Rat Genome 230 2.0 Array	GeneChip® Operating Software Version 1.4, Affymetrix analyzer.	Thirty-nine genes that showed more than a 2-fold increase in expression after administration of VPP and IPP, Fourteen genes that showed less than a 0.5-fold decrease in expression	Yamaguchi N et al. (48)
SHR and WKY	brain, heart, kidney and liver	UniSet Rat I Expression Bioarray, validation by RT-PCR of 9 genes	F-test and unpaired t test. CodeLink Expression Analysis Software, GenePix Pro 6.0 Software, GeneSpring software	60 genes were differentially expressed in the heart of SHRSP rats. Of these, five genes were up-regulated and 55 genes were down-regulated.	Kato N et al. (51)
SHR, LHR, heterozygous TGR(mRen2)27 rat, and their respective controls	heart	Affymetrix GeneChip Rat Expression Array RAE230A, validation by qPCR of 6 genes.	Affymetrix Microarray Suite 5.0 software, significance analysis of microarrays (SAM) 1.21 software	Only four genes had significantly modified expression in the three hypertensive models among which a single gene, coding for sialyltransferase 7A, was consistently overexpressed	Cerutti C et al. (49)
WKY	Kidney and aorta.	Affymetrix rat genome 230A array, validation by RT-PCR	software R together with its bioinformatics packages collected in the Bioconductor project	Six functionally known genes (Igfbp1, Xdh, Sult1a1, Mawbp, Por, and Gstm1) and two expressed sequence tags (BI277460 and AI411345) were significantly upregulated	Westhoff TH et al. (56)

Animal model and the control group	Tissue	Microarray platform	Software	Observations	References
Female C57Bl/6J mice	Blood, heart and liver	Mouse NIH 15K cDNA microarrays	Expression Profiler tool EPCLUST	L-NNA and BSO both caused hypertension. Gene expression was regulated in cytoskeletal components in both models, protein synthesis in L-NNA-treated mice, and energy metabolism in BSO-treated mice.	Chon H et al. (41)
SHR and WKY	kidney	Affymetrix rat RG-U34A array	Normalisation and scaling using GeneChip suite.	20 genes were down-regulated and 7 genes were up-regulated in SHR	Hinojos CA et al. (50)
SHR and WKY	heart	Affymetrix Rat Genome U34A GeneChips	Affymetrix software, GeneSpring software	Comparison of LV RNA profiles from 20- and 12-month-old SHR identified 61 known genes and 20 ESTs, whose expression was upregulated >1.5-fold, and 31 known genes and 15 ESTs, whose expression was downregulated >1.5-fold.	Rysä J et al. (57)
Sabra rat	kidney	Affymetrix Rat Genome RAE230 GeneChip, validation by RT-PCR of 7 genes.	Affymetrix software	2470 transcripts were differentially expressed between the study groups. Cluster analysis identified genome-wide 192 genes that were relevant to salt-susceptibility and/or hypertension, 19 of which mapped to chromosome 1.	Yagil C et al. (58)
<i>Nppa</i> ^{+/+} and <i>Nppa</i> ^{-/-} mice	Heart, Lung, kidney, brain, liver, and spleen	mouse microarray membranes (GeneFilter GF-400 membranes)	software package	Expression of 80 genes was elevated >2-fold and expression of 10 was reduced to <0.5 in 7-day TAC <i>Nppa</i> ^{+/+} compared with control	Dajun Wang et al. (59)

Animal model and the control group	Tissue	Microarray platform	Software	Observations	References
SHR and WKY	Kidney, spleen, and liver	Affymetrix Rat U34 array set validation by qRT-PCR	Affymetrix MAS 5.0	There was a significant reduction in expression of glutathione S-transferase mu-type 2, a gene involved in the defense against oxidative stress	Martin W. McBride et al. (60)
SHR	kidney	Affymetrix Rat Genome U34A arrays	Software package	Of the 8,799 known genes and expressed sequence tag (EST) clusters of Affymetrix Rat Genome U34A arrays, 74 differentially expressed transcripts, of which 43 were up-regulated and 31 were down-regulated in SHR.	Koo et al. (54)
SHR and WKY	kidney	cDNA Rat version 2.0 Chip, validation by Northern blot and RT-PCR	ArraySuite version 2.0	22 genes at 3 weeks of age and 104 genes at 9 weeks of age were differentially expressed in SHR compared with WKY in renal gene expression.	Seubert et al. (55)

SHR, spontaneously hypertensive rats. WKY, Wistar-Kyoto rats, usually used for the control the experimental group. WTR, wild-type rats. BNR, Brown Norway rats. LHR, Lyon hypertensive rats. SDR, Sprague-Dawley rats.

Table 2. Animals' microarray studies utilizing target organ tissue.

3. Summary and conclusions

Gene expression profiling provides a phenotypic resolution not feasible with standard clinical criteria. Differences in the gene expression profiles found in these studies identify markers useful for diagnostic, prognostic and therapeutic purposes. These findings emphasize the utility of whole blood and target organs as surrogate tissues for gene expression profiling. Gene expression profiling of different animal models of essential hypertension, and comparison of these profiles with human essential hypertension, will assist in determining the complex pathways that comprise the pathobiology of essential hypertension and help with the diagnostic, prognostic and therapeutic purposes in the future.

4. References


- [1] Delles C, McBride MW, Graham D, Padmanabhan S, Dominiczak AF. Genetics of hypertension: from experimental animals to humans. *Biochim Biophys Acta*. 2010;1802(12):1299-308.

- [2] Ashitate T, Osanai T, Tanaka M, Magota K, Echizen T, Izumiyama K, Yokoyama H, Shibutani S, Hanada K, Tomita H, Okumura K Overexpression of coupling factor 6 causes cardiac dysfunction under high-salt diet in mice. *J Hypertens.* 2010; 28(11):2243-51.
- [3] Denton D. *The Hunger for Salt: An Anthropological, Physiological and Medical Analysis.* Berlin, Germany: Springer Verlag; 1982.
- [4] Elliott P. The intersalt study: an addition to the evidence on salt and Blood pressure and some implications. *J Hum Hypertens.* 1989; 3: 289-298.
- [5] Goodfriend TL, Ball DL, Egan BM, Campell WB, Nithipatikan K, Obesity; Sleep apnea, and aldosterone: theory and therapy. *Hypertension.* 2004; 43:518-524.
- [6] Delva, P., Pastori, C, Provoli, E., Degan, M., Arosio, E., Montesi, G., Steele, A. & Lechi, A. Erythrocyte Na(-)-H-H exchange activity in essential hypertensive and obese patients: role of excess body weight. *J Hypertens.* 1993; 11, 823.
- [7] Chintanadilok, J., Exercise in Treating Hypertension, *PhysSports Med.* 2002; 11-23.
- [8] Urata, H., Antihypertensive and volume-depleting effects of mild exercise on essential hypertension. *Hypertension.* 1987; 9: 245-52.
- [9] Sanders, B.J. & Lawler, J.E. The borderline hypertensive rat (BHR) as a model for environmentally- induced hypertension: a review and update. *Neurosci Biobehav Rev.* 1992;16, 207.
- [10] Schnall, P.L., Pieper, C, Schwartz, J.E., Karasek, R.A., Schluskel, Y., Devereux, R.B., Ganau, A., Alderman, M., Warren, K. & Pickering, T.G. The relationship between 'job strain,' workplace diastolic blood pressure, and left ventricular mass index. Results of a case-control study [published erratum appears in *JAMA* 1992 Mar 4;267(9): 12091 [see comments]. *Jama*, 1990; 263, 1929.
- [11] Tuomilehto J, Elo J, Nissmen A. Smoking among patients with malignant hypertension. *BMJ.* 1982; 1:1086.
- [12] Beevers G et al. The pathophysiology of Hypertension. *BMJ* 2001; 322: 912-916.
- [13] Keamey PM et al. Global burden of hypertension: analysis of worldwide data. *Lancet* 2005;365:217-223.
- [14] Perry IJ, Whincup PH, Shaper AG. Environmental factors in the development of essential hypertension, *British medical Bulletin* 1994; 50: 246-259.
- [15] Beilin, L.J. Alcohol and hypertension. *Clin Exp Pharmacol Physiol*, 1995; 22, 185.
- [16] Chen L, Smith GD, Harbord RM, Lewis SJ. Alcohol intake and Blood pressure: A systematic Review implementing a Mendelian Randomization Approach. *PLOS Med* 2008;s(3):e s2.
- [17] Klatsky, A.L. Alcohol and hypertension. *Clin Chim Acta*, 1996; 246,91.
- [18] Klatsky AL. Blood pressure and alcohol intake. In: Laragh JH, Brenner BM, eds. *Hypertension: pathophysiology, diagnosis, and management.* 2nd ed. New York: Raven Press, 1995:2649-67.
- [19] Grobbee, D.E. Electrolytes and hypertension: results from recent studies. *Am J Med Sci*, 1994; 307 Suppl 1, S17.
- [20] Krishna, G.G. Role of potassium in the pathogenesis of hypertension. *Am J Med Sci*, 1994; 301 Suppl 1,S2.
- [21] Feinleib M, Garrison RJ, Fabsitz R, Christian JC, Hrubec Z, Borhani NO, et al. The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. *Am J Epidemiol.* 1977; 106:284-5.

- [22] Trevisan, C, Saia, A., Schergna, E. & Mantero, F. The Prader-Willi syndrome: neuroendocrine study of identical twins. *Ital J Neurol Sci*, 1983; 4, 79.
- [23] Longini IM Jr, Higgins MW, Hinton PC, Moll PP, Keller JB. Environmental and genetic sources of familial aggregation of blood pressure in Tecumseh, Michigan. *Am J Epidemiol*. 1984; 120:131-44.
- [24] Carmelli, D., Robinette, D. & Fabsitz, R. Concordance, discordance and prevalence of hypertension in World War II male veteran twins. *J Hypertens*, 1994; 12:323.
- [25] True, W.R., Romeis, J.C, Heath, A.C, Flick, L.H., Shaw, L., Eisen, S.A., Goldberg, J. & Lyons, M.J. Genetic and environmental contributions to healthcare need and utilization: a twin analysis. *Health Serv. Res*, 1997; 32, 37.
- [26] Rishi AS, Nelson ND, Goyal A. DNA microarrays: gene expression profiling in plants. *Reviews in Plant Biochemistry and Biotechnology* 1:81-100.
- [27] van Hal NLW, Vorst O, van Houwelingen AMML, Kok ET, Peijnenburg A, Aharoni A, van Tune AJ, Keijer J. The application of DNA microarrays in gene expression analysis. *Journal of Biotechnology*; 78:271-280.
- [28] Streit S, Michalski CW, Erkan M, Kleff J, Fries H. Northern blot analysis for detection and quantification of RNA in Pancreatic cancer cells and tissues. *Natruue protocols*. 2009; 4(1): 37-43.
- [29] Bertoli, D. J., U. H. Schlichter, M. J. Adams, P. R. Burrows, H. H. Steinbiss, and J. F. Antoniwi. An analysis of differential display shows a strong bias towards high copy number mRNAs. *Nucleic Acids Res*. 1995; 23:4520-4523.
- [30] Berezowsky C, Bag J, Developmentally regulated slow troponin C messenger RNA in chicken skeleton and cardiac muscles. *Biochem cell Biol*. 1988; 66:880-888.
- [31] Mercadier JJ, Zongazo MA, Wisnewsky C, Butler-Brown G. Atrial natriuretic factor mRNA and peptide in the human heart during ontogenic development. *Biochem Biophys Res. Comm*.1989;159:777-782.
- [32] Swynghedauw B, Moalic JM, Bouveret P, Bercovici J, de la Bastie D, Schwartz. mRNA content and complexity in animal and overloaded rat heart: a preliminary report. *Eur Heart J*.1984; 5suppl:211-217.
- [33] Chen H, Yu SL, Chen WJ, Yang PC, Chien CT, Chou HY, Li HN, Peck K, Huang CH, Lin FY, Chen JJ, Lee YT. Dynamic changes of gene expression profiles during post-natal development of the heart in mice. *Heart*. 2004;90:927-934.
- [34] Velculescu, V. E., Zhang, L., Vogelstein, B., and Kinzler, K. W. Serial Analysis Of Gene Expression. *Science*. 1995; 270:484-487.
- [35] Ye SQ, Lavoie T, Usher DC, Zhang LQ. Microarray, SAGE and their application to cardiovascular disease. *Cell Res*. 2002;12:705-115.
- [36] Anisimov SV, Boheller KR. Aging-associated changes in cardiac gene expression: large-scale transcriptome analysis. *Adv. Gerontol*.2003;11:67-75.
- [37] Liang, P., Pardee, A.B., Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. *Science*1992; 257, 967-971.
- [38] Spinola S, Cannon J. *J Immunol Methods*1985; 81:161-5.
- [39] Craig PS, Rogan MT, Campos-Ponce M. *Parasitology*. 2003;127 Suppl: S5-20.
- [40] Sargent TD, Dawid IB. Differential gene expression in the gastrula of *xenopus laevis*. *Science*. 1983;222:135-139.
- [41] Chon et al. Broadly Altered Gene Expression in Blood Leukocytes in Essential Hypertension is Absent During Treatment. *Hypertension* 2004;43:947-951.

- [42] Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. *Science* 1995;270:467-70.
- [43] Schena M. *Microarray biochip technology*. Sunnyvale, CA: Eaton Publishing; 2000.
- [44] Friese RS, Mahboubi P, Mahapatra NR, Mahata SK, Schork NJ, Schmid-Schonbein GW, O'Connor DT. Common genetic mechanisms of blood pressure elevation in two independent rodent models of human essential hypertension. *Am J Hypertens*. 2005;18:633-652.
- [45] Korkor MT, Meng FB, Xing SY, Zhang MC, Guo JR, Zhu XX, Yang P. Microarray Analysis of Differential Gene expression profile in peripheral Blood Cells of Patients with Human Essential Hypertension. *Int.J. Med Sci*.2011;8(2):168-179.
- [46] Simeone SM, Li MW, Paradis P, Schiffrin EL. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. *Physiol Genomics*. 2011; 11;43(3):148-60.
- [47] Barchiesi F, Lucchinetti E, Zaugg M, Ogunshola OO, Wright M, Meyer M, Rosselli M, Schaufelberger S, Gillespie DG, Jackson EK, Dubey RK. Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection. *Hypertension*. 2010 56(5):964-72.
- [48] Rysa J, Leskinen H, Ilves M, Ruskoaho H. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. *Hypertension*. 2005;45:927-933.
- [49] Cerutti C, Kurdi M, Bricca G, Hodroj W, Paultre C, Randon J, Gustin MP. Transcriptional alterations in the left ventricle of three hypertensive rat models. *Physiol Genomics*. 2006;27:295-308.
- [50] Hinojos CA, Boerwinkle E, Fornage M, Doris PA. Combined genealogical, mapping, and expression approaches to identify spontaneously hypertensive rat hypertension candidate genes. *Hypertension*. 2005;45(4):698-704.
- [51] Kato N, Liang YQ, Ochiai Y, Jesmin S. Systemic evaluation of gene expression changes in major target organs induced by atorvastatin. *Eur J Pharmacol*. 2008;28;584(2-3):376-89. Epub 2008 Feb 8.
- [52] Clemitson JR, Dixon RJ, Haines S, Bingham AJ, Patel BR, Hall L, Lo M, Sassard J, Charchar FJ, Samani NJ. Genetic dissection of a blood pressure quantitative trait locus on rat chromosome 1 and gene expression analysis identifies SPON1 as a novel candidate hypertension gene. *Circ Res*. 2007;100:992-999.
- [53] Timofeeva AV, Goriunova LE, Khaspekov GL, Il'inskaia OP, Sirotkin VN, Andreeva ER, Tararak EM, Bulkina OS, Buza VV, Britareva VV, Karpov IuA, Bibilashvili RSh. Comparative transcriptome analysis of human aorta atherosclerotic lesions and peripheral blood leukocytes from essential hypertension patients. *Kardiologiya*. 2009;49(9):27-38.
- [54] Koo JR, Liang KH, Vaziri ND. Microarray Analysis of Altered Gene Expression in Kidneys of Adult spontaneously Hypertensive Rats. *The journal of Applied Research*. 2004;4:111-126.
- [55] Seubert JM, XU F, Graves JP, Collins JB, Sieber SO, Paules RS, Kroetz DL, Zeldin DC. Differential renal gene expression in prehypertensive and hypertensive spontaneously hypertensive rats. *AmJ Physiol Renal Physiol*. 2005; 289: 552-561.

- [56] Westhoff TH, Scheid S, Tölle M, Kaynak B, Schmidt S, Zidek W, Sperling S, van der Giet M. A physiogenomic approach to study the regulation of blood pressure. *Physiol Genomics*. 2005; 21;23(1):46-53.
- [57] Rysä J, Leskinen H, Ilves M, Ruskoaho H. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. *Hypertension*. 2005; 45(5):927-33.
- [58] Yagil C, Hubner N, Monti J, Schulz H, Sapojnikov M, Luft FC, Ganten D, Yagil Y. Identification of hypertension-related genes through an integrated genomic-transcriptomic approach. *Circ Res*. 2005;96(6):617-25.
- [59] Wang D, Oparil S, Feng JA, Li P, Perry G, Chen LB, Dai M, John SW, Chen YF. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. *Hypertension*. 2003; 42(1):88-95.
- [60] Liang M, Yuan B, Rute E, Greene AS, Olivier M, Cowley AW Jr. Insights into Dahl salt-sensitive hypertension revealed by temporal patterns of renal medullary gene expression. *Physiol Genomics*. 2003; 12(3):229-37.



Genetics and Pathophysiology of Essential Hypertension

Edited by Prof. Madhu Khullar

ISBN 978-953-51-0282-3

Hard cover, 236 pages

Publisher InTech

Published online 09, March, 2012

Published in print edition March, 2012

This book, authored by renowned researchers in the field of Hypertension Research, details the state of the art knowledge in genetics, genomics and pathophysiology of Essential hypertension, specifically the genetic determinants of hypertension and role of gene variants in response to anti-hypertensive therapy. Two chapters describe mitochondrial mutations in Essential hypertension and in hypertension associated Left ventricular hypertrophy, one chapter reviews in detail the global gene expression in hypertension, and an up to date treatise on pathophysiology of resistant hypertension is detailed in another chapter. Other topics included in the book are end organ damage, baroreceptor sensitivity and role of music therapy in essential hypertension.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Ping Yang (2012). Differential Gene Expression Profile in Essential Hypertension, Genetics and Pathophysiology of Essential Hypertension, Prof. Madhu Khullar (Ed.), ISBN: 978-953-51-0282-3, InTech, Available from: <http://www.intechopen.com/books/genetics-and-pathophysiology-of-essential-hypertension/gene-expression-microarray-technology-in-hypertension-research>

INTECH

open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.